This is a preview of subscription content, log in via an institution to check access.
Notes
2015 British pounds
Reference
Rothwell B, et al. Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England. PharmacoEconomics-Open : 17 Dec 2020. Available from: URL: https://doi.org/10.1007/s41669-020-00245-4
Rights and permissions
About this article
Cite this article
Cost effectiveness of nivolumab in advanced NSCLC. PharmacoEcon Outcomes News 869, 7 (2021). https://doi.org/10.1007/s40274-021-7374-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7374-z